Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Res. 2017 Jan 10;15(3):269–280. doi: 10.1158/1541-7786.MCR-16-0227-T

Figure 1. Cells expressing P242R are resistant to cisplatin in vitro and in vivo.

Figure 1

MCF7 (A) or A549 (B) cells expressing WT or P242R Pol β or containing empty vector were treated with varying concentrations of cisplatin (0-12.5 μM). Clonogenic survival assays were performed, and data are presented as mean ± SEM of the percent survival (n = 3-6). C-D. Mouse xenografts of A549 tumors expressing either WT (circles) or P242R (triangles) Pol β were treated by intraperitoneal injection once per week with either saline (dashed lines, open symbols) or 4 mg/kg cisplatin (solid line, closed symbols). Tumor growth measurements are presented as mean ± SEM (n=5). *, **, ***, or **** represent p<0.05, 0.01, 0.001, or 0.0001, respectively, comparing cisplatin-treated tumors to saline at each time point.